Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease

Data from the PROactive Study (PROactive 08)

  1. Erland Erdmann, MD, FESC, FACC1,
  2. Bernard Charbonnel, MD2,
  3. Robert G. Wilcox, MD3,
  4. Allan M. Skene, PHD4,
  5. Massimo Massi-Benedetti, MD5,
  6. John Yates, MD6,
  7. Meng Tan, MD7,
  8. Robert Spanheimer, MD8,
  9. Eberhard Standl, MD9,
  10. John A. Dormandy, FRCS, DSC10 and
  11. On behalf of the PROactive investigators
  1. 1Medizinische Klinik III der Universität zu Köln, Köln, Germany
  2. 2Clinique d'Endocrinologie, Hôtel Dieu, Nantes, France
  3. 3Queen's Medical Centre, University Hospital, Nottingham, U.K
  4. 4Nottingham Clinical Research Limited, Nottingham, U.K
  5. 5Medicine and Metabolic Diseases, University of Perugia, Perugia, Italy
  6. 6Medical Research and Development, Takeda Global Research and Development Center, Deerfield, Illinois
  7. 7Lilly Research Laboratories, Eli Lilly, Indianapolis, Indiana
  8. 8Medical and Scientific Affairs, Takeda Pharmaceuticals North America, Deerfield, Illinois
  9. 9Munich Institute of Diabetes Research and Medical Department, Krankenhaus Munchen-Schwabing, Munich, Germany
  10. 10St. George's Hospital, London, U.K
  1. Address correspondence and reprint requests to Dr. Erland Erdmann, Medizinische Klinik III der Universität zu Köln Kerpener Str. 62, D-50937 Köln, Germany. E-mail: erland.erdmann{at}uni-koeln.de

Abstract

OBJECTIVE— PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) enrolled patients with type 2 diabetes and preexisting cardiovascular disease. These patients were at high risk for heart failure, so any therapeutic benefit could potentially be offset by risk of associated heart failure mortality. We analyzed the heart failure cases to assess the effects of treatment on morbidity and mortality after reports of serious heart failure.

RESEARCH DESIGN AND METHODS— PROactive was an outcome study in 5,238 patients randomized to pioglitazone or placebo. Patients with New York Heart Association Class II–IV heart failure at screening were excluded. A serious adverse event of heart failure was defined as heart failure that required hospitalization or prolonged a hospitalization stay, was fatal or life threatening, or resulted in persistent significant disability or incapacity. Heart failure risk was evaluated by multivariate regression.

RESULTS— More pioglitazone (5.7%) than placebo patients (4.1%) had a serious heart failure event during the study (P = 0.007). However, mortality due to heart failure was similar (25 of 2,605 [0.96%] for pioglitazone vs. 22 of 2,633 [0.84%] for placebo; P = 0.639). Among patients with a serious heart failure event, subsequent all-cause mortality was proportionately lower with pioglitazone (40 of 149 [26.8%] vs. 37 of 108 [34.3%] with placebo; P = 0.1338). Proportionately fewer pioglitazone patients with serious heart failure went on to have an event in the primary (47.7% with pioglitazone vs. 57.4% with placebo; P = 0.0593) or main secondary end point (34.9% with pioglitazone vs. 47.2% with placebo; P = 0.025).

CONCLUSIONS— Although the incidence of serious heart failure was increased with pioglitazone versus placebo in the total PROactive population of patients with type 2 diabetes and macrovascular disease, subsequent mortality or morbidity was not increased in patients with serious heart failure.

Footnotes

  • Published ahead of print at http://care.diabetesjournals.org on 31 July 2007. DOI: 10.2337/dc07-0717.

    Additional information for this article can be found in an online appendix at http://dx.doi.org/10.2337/dc07-0717.

    E.E., B.C., R.G.W., M.M.-B., E.S., and J.A.D. have served as consultants to and have received honoraria for speaking engagements from Takeda. A.M.S. is Managing Director of Nottingham Clinical Research Group, which was contracted by Takeda. J.Y. is a previous employee of Takeda. M.T. is currently an employee of Takeda.

    A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.

    • Accepted July 23, 2007.
    • Received April 16, 2007.
« Previous | Next Article »Table of Contents

This Article

  1. Published online before print July 31, 2007, doi: 10.2337/dc07-0717 Diabetes Care November 2007 vol. 30 no. 11 2773-2778
  1. » Abstract
  2. Full Text
  3. Full Text (PDF)
  4. Online-Only Appendix
  5. All Versions of this Article:
    1. dc07-0717v1
    2. 30/11/2773 most recent

Current Issue

  1. November 2009, 32 (11)
  1. Current Issue
  1. Alert me to new issues of Diabetes Care